基于转录组的肝细胞癌分子分型研究进展  

Progress in transcriptomic molecular subtyping of hepatocellular carcinoma

作　　者：赵洋 张勇 燕蒙 王子叶 应万涛 钱小红[1,2] ZHAO Yang;ZHANG Yong;YAN Meng;WANG ZiYe;YING WanTao;QIAN XiaoHong(College of Life Science and Bioengineering,Beijing University of Technology,Beijing 100124,China;Beijing Institute of Lifeomics,State Key Laboratory of Proteomics,Beijing Proteome Research Center,National Center for Protein Sciences (Beijing),Beijing 102206,China)

机构地区：[1]北京工业大学生命科学与生物工程学院,北京100124 [2]军事科学院军事医学研究院生命组学研究所蛋白质组学国家重点实验室北京蛋白质组研究中心国家蛋白质科学中心-北京,北京102206

出　　处：《中国科学：生命科学》2019年第1期10-17,共8页Scientia Sinica(Vitae)

基　　金：国家基础研究重点项目(批准号:2017YFC0906600;2016YFA0501300);北京市科技计划项目(批准号:Z161100002616036);军事医学创新工程专项(批准号:16CXZ027)资助

摘　　要：肝细胞癌是恶性程度极高的肿瘤之一,患者的发病率和死亡率都位居恶性肿瘤前列.虽然传统临床病理诊断和分级治疗策略得到了极大的发展,并显著改善了肝细胞癌患者的生存情况,但至今肝细胞癌患者的5年生存率仍然较低.基因测序技术的进步和发展加速了肿瘤基因组学的研究,也帮助科学家认识了肿瘤的异质性及其发生、发展的分子机制.近20年,科学家基于转录组数据提出了许多与病理特征相关的肝细胞癌分子亚型,并对其生物学特性和分子特征进行了深入的挖掘.若能将转录组分子亚型与临床病理分级系统综合考虑,用于肝细胞癌病理诊断和分级治疗,将有望改善病人的生存情况,推进肝细胞癌病人的个体化医疗进程.Hepatocellular carcinoma(HCC) is one of the most malignant tumors in the world. The incidence and mortality rates of HCC are among the highest in malignant tumors. Although advances in the developing of clinical staging system have led to significant improvement in the survival of HCC patients, the 5-year survival rates are still very poor. Advances in genome sequencing technology are now supporting a breadth of cancer genome characterization studies and help scientists to understand the heterogeneity of HCC tumors and the molecular mechanisms of its occurrence and progression. In the past 20 years, scientists have proposed a number of transcriptomic HCC molecular subtypes that are significantly associated with pathological features, and have an in-depth exploration of their biological properties and molecular characteristics. Thus, we suppose that integrated transcriptomic HCC subtypes into traditional clinical staging systems will greatly improve molecular classification and prediction of outcomes in HCC and enable personalized HCC treatment.

关 键 词：肝细胞癌 转录组 分子亚型 生存率 

分 类 号：R735.7[医药卫生—肿瘤]